Who are Other DPP4-i's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): DPP4 inhibitor.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/other-dpp4-i.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

Other DPP4-i — Competitive Intelligence Brief

Other DPP4-i (Other DPP4-i) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: DPP4 inhibitor. Area: Diabetes.

marketed DPP4 inhibitor DPP4 (Dipeptidyl peptidase-4) Diabetes Small molecule Live · refreshed every 30 min

Target snapshot

Other DPP4-i (Other DPP4-i) — Bangladesh Institute of Research and Rehabilitation in Diabetes, Endocrine and Metabolic Disorders. DPP4 inhibitors block the enzyme dipeptidyl peptidase-4, which prolongs the action of incretin hormones to increase insulin secretion and lower blood glucose in type 2 diabetes.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Other DPP4-i TARGET	Other DPP4-i	Bangladesh Institute of Research and Rehabilitation in Diabetes, Endocrine and Metabolic Disorders	marketed	DPP4 inhibitor	DPP4 (Dipeptidyl peptidase-4)
DPP4 inhibitor	DPP4 inhibitor	AstraZeneca	marketed	DPP4 inhibitor	DPP4 (dipeptidyl peptidase-4)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (DPP4 inhibitor class)

AstraZeneca · 1 drug in this class
Bangladesh Institute of Research and Rehabilitation in Diabetes, Endocrine and Metabolic Disorders · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Other DPP4-i — Competitive Intelligence Brief. https://druglandscape.com/ci/other-dpp4-i. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab